Table 1 Correlation of MTA1 and EpCAM with clinicopathological characteristics of lung cancer patients
From: MTA1-upregulated EpCAM is associated with metastatic behaviors and poor prognosis in lung cancer
Variables | MTA1 | EpCAM | ||||
|---|---|---|---|---|---|---|
Low | High | p | Low | High | p | |
(N = 118) | 53 | 65 | 51 | 67 | ||
Age (years)a | ||||||
> = 57 (65) | 28 | 37 | 0.66 | 26 | 39 | 0.44 |
<57 (53) | 25 | 28 | 25 | 28 | ||
Gender | ||||||
Male (90) | 45 | 45 | 0.05 | 42 | 48 | 0.20 |
Female (28) | 8 | 20 | 9 | 19 | ||
Histopathologic types | ||||||
SCC (35) | 21 | 14 | 0.02 | 19 | 16 | 0.02 |
ADC (46) | 14 | 32 | 14 | 32 | ||
LCC (8) | 3 | 5 | 5 | 3 | ||
SCLC (13) | 8 | 5 | 9 | 4 | ||
Othersb (16) | 6 | 10 | 4 | 12 | ||
Differentiation | ||||||
Well (24) | 15 | 9 | 0.12 | 11 | 13 | 0.85 |
Moderate (26) | 9 | 17 | 10 | 16 | ||
Poorly (68) | 29 | 39 | 30 | 38 | ||
Tumor diameter, cm | ||||||
<3 (12) | 9 | 3 | 0.04 | 6 | 6 | 0.78 |
3–5 (75) | 34 | 41 | 33 | 42 | ||
>5 (31) | 10 | 21 | 12 | 19 | ||
Local advance | ||||||
T1,2 (94) | 46 | 48 | 0.11 | 42 | 52 | 0.65 |
T3,4 (24) | 7 | 17 | 9 | 15 | ||
Lymph node metastasis | ||||||
N0 (53) | 35 | 18 | 0.01 | 30 | 23 | 0.01 |
N1,2,3 (65) | 18 | 47 | 21 | 44 | ||
Clinical stage | ||||||
I/II (71) | 43 | 28 | 0.01 | 37 | 34 | 0.02 |
IIIA (47) | 10 | 37 | 14 | 33 | ||
Smoking status | ||||||
No (45) | 13 | 32 | 0.01 | 13 | 32 | 0.02 |
Yes (73) | 40 | 33 | 38 | 35 | ||
Neoadjuvant treatment | ||||||
NO (36) | 21 | 15 | 0.07 | 19 | 17 | 0.20 |
Yes (82) | 32 | 50 | 32 | 50 | ||